Current status on Leishmania vaccine: An overview

Current treatment against leishmaniasis is solely based on chemotherapy and vaccination remains an alternative for the prevention and control of this dreadful parasitic disease. Extensive proof from animal experimental models indicates that a robust protection can be conferred by immunization with defined subunit vaccines or live-attenuated strains of Leishmania. However, to date, no such vaccine is on hand in spite of substantial efforts. This current study focuses on recent findings in anti-leishmania vaccine field and highlights current difficulties facing vaccine development and its implementation.

Autorentext

Manas Ranjan Dikhit est né dans un petit village, Badala Sasan, à Bhubaneswar, en Inde. Il a obtenu le B.Sc. de l'Université d'Utkal, le M.Sc. de l'OUAT et le doctorat de l'Université de Calcutta, en Inde. En 2007, le Dr Manas a rejoint le RMRIMS (ICMR) en tant que scientifique. Il a publié plus de 60 articles de recherche et s'intéresse principalement à la leishmaniose viscérale.